Adcytherix, a Marseille, France-based biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC), raised €30M in Seed funding.
The round was led by Pontifax with participation from Pureos Bioventures, RA Capital Management, Dawn Biopharma (a platform controlled by KKR) and the management of the company.
The company intends to use the funds to expand operations and its development efforts.
Co-founded by Jack Elands and Pontifax Venture Capital with Xavier Preville and Carsten Dehning, Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat need diseases such as cancer.
As part of the seed round financing, Ran Nussbaum and Ohad Hammer of Pontifax, Ximing Ding of Pureos Bioventures, Iyona Rajkomar of Dawn Biopharma and Matthew Hammond of RA Capital Management joined the supervisory committee of Adcytherix.
FinSMEs